^
Association details:
| Biomarker: | SERPINB3 mutation |
|---|---|
| Cancer: | Melanoma |
| Drug Class: | CTLA4 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Recurrent SERPINB3 and SERPINB4 mutations in patients who respond to anti-CTLA4 immunotherapy
Excerpt:
Here we show that somatic mutations in SERPINB3 and SERPINB4 are associated with survival after anti-CTLA4 immunotherapy in two independent cohorts of patients with melanoma (n = 174). These mutations were strongly associated with overall survival following therapy in both independently collected cohorts.
DOI:
10.1038/ng.3677
